Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Shares disturbing details
House to vote on McCarthy
Hunter pleads not guilty
Expecting 1st child together
Shoplifter sets clerk on fire?
Two children drown in pool
Govt. sues Union Pacific
Settles assault lawsuit
Abduction suspect found
Olympics writer dies at 61
‘Selling personal belongings'
14-year-old fatally shoots 3?
Faces dog fighting charges
First-ever space debris fine
29 soldiers killed in Niger
Jackpot rises to $1.2B
Customers regain upper hand
2 soldiers killed, dozen hurt
DNC diversity goals
Joins Mich. Senate race
Evergrande shares soar
Panda diplomacy
Ethics violation allegations
Heartburn drug suits settled
X Social Media sues X
Nobel winner presidency bid
Healthcare strike looms
Ohio human trafficking bust
Diplomatic tensions escalate
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
164,000 results
WISH-TV
5d
Health Spotlight: First FDA-approved drug to slow Alzheimer’s
More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...
12don MSN
Medical Moment: FDA approves first-ever drug to slow Alzheimer’s
There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
朝日新聞社3d
US approves Alzheimer’s drug that modestly slows disease
FDA approves much-debated Alzheimer’s drug panned by experts June 8, 2021 Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus ...
GEN2h
Obesity, Alzheimer’s Drugs to Drive Sales as Patent Cliff Concerns Ebb
The largest biopharmas are succeeding in overcoming the so-called patent cliff of sharply reduced future sales as existing blockbuster drugs lose patent protection—at least over the next five years, a ...
5d
FDA advisers vote against experimental ALS treatment pushed by patients
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...
Forbes22d
What To Know About The Alzheimer’s Drug Leqembi
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
7d
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
4don MSN
FDA wants to regulate thousands of lab tests that have long skirted oversight
The Food and Drug Administration says it plans to begin regulating laboratory-based medical tests. It's a multibillion-dollar ...
The Financial Times1mon
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
WTOP News19d
New Treatments for Alzheimer’s Disease
For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.
1don MSN
Alzheimer’s Association makes progress on treating Alzheimer’s and dementia
Progress is being made in treating Alzheimer’s and Dementia, one individual with the Alzheimer's Association is optimistic that a full treatment could be available within her lifetime.
7d
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices